Risankizumab, a therapeutic alternative for psoriasis in people living with HIV.
Tomás EstevinhoEgídio FreitasTiago TorresPublished in: The Journal of international medical research (2024)
The management of psoriasis in individuals with human immunodeficiency virus (HIV) presents a unique challenge, marked by a more severe progression and limited efficacy of first- and second-line treatments. Although conventional systemic therapies might be considered, these agents are immunosuppressants, making their use challenging in people living with HIV (PLHIV). Biologic agents are frequently used in individuals with moderate-to-severe psoriasis, but their efficacy and safety data in PLHIV are very limited, as this patient group tends to be excluded from clinical trials. Risankizumab is a selective interleukin-23 (IL-23) inhibitor that has demonstrated a favourable safety profile and high efficacy in long-term studies and clinical practice. This current case report presents two clinical cases of PLHIV with plaque psoriasis who were effectively treated with the biologic agent risankizumab, with no reported safety issues. Although there are limited data on the use of biologics in PLHIV, this case series suggests that IL-23 inhibitors, namely risankizumab, might be a valuable therapeutic option for this population. Additional research and larger studies are needed to gain a more comprehensive understanding of the long-term safety and efficacy of IL-23 inhibitors in individuals affected by HIV.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hepatitis c virus
- case report
- hiv infected
- hiv positive
- hiv aids
- clinical trial
- rheumatoid arthritis
- clinical practice
- hiv testing
- atopic dermatitis
- early onset
- big data
- electronic health record
- coronary artery disease
- machine learning
- case control
- drug induced
- men who have sex with men
- open label
- deep learning
- south africa